![]() Bio-Techne Bio-Techne is a company that provides researchers in life science and clinical diagnostics with reagent instruments, custom manufacturing, and testing services. | ![]() Humanigen Humanigen is repositioning and developing its proprietary monoclonal antibodies to meet some critical unmet needs in cancer science. | |||
Founding Date | Founding Date 2002 | Founding Date 1981 | Founding Date 2000 | Founding Date 1842 |
Type | Type Subsidiary | Type Public | Type Public | Type Subsidiary |
Tags | ||||
Locations | Locations San Diego, US HQ Beijing, CN Tokyo, JP | Locations Minneapolis, US HQ Toronto, CA Praha, CZ Copenhagen, DK Noyal Châtillon Sur Seiche, FR Noyal Châtillon Sur Seiche, FR Planegg, DE see more | Locations Burlingame, US HQ Dublin, IE London, GB Kansas City, US | Locations Guildford, GB HQ São José Dos Campos, BR Sofia, BG Milton, CA Pointe Claire, CA Vaughan, CA Beijing, CN see more |
Employees | Employees 6571% decrease | Employees 3,0502% increase | Employees 233% decrease | Employees 9465% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 11.2 b | Valuation ($) 4.3 m | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $1.2b (FY, 2025) | Revenue (est.) $2.5m (FY, 2022) | Revenue (est.) £165.1m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $429.4m (FY, 2025) | Cost of goods N/A | Cost of goods £111m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $790.3m (FY, 2025) | Gross profit N/A | Gross profit £54.1m (FY, 2025) |
Net income | Net income N/A | Net income $73.4m (FY, 2025) | Net income ($70.7m) (FY, 2022) | Net income £13.9m (FY, 2025) |
Operating ⚠ | ||||
Patent Applications | Patent Applications N/A | Patent Applications 270 (FY, 2022) | Patent Applications 17 (FY, 2017) | Patent Applications N/A |

Bio-Techne is a company that provides researchers in life science and clinical diagnostics with reagent instruments, custom manufacturing, and testing services.
View company
Humanigen is repositioning and developing its proprietary monoclonal antibodies to meet some critical unmet needs in cancer science.
View company